港股异动 | 歌礼制药-B(01672)早盘涨近10% 治疗肥胖症药物研究获积极顶线结果已向FDA提交IIa期研究方案

智通财经2025-04-24

智通财经APP获悉，歌礼制药-B(01672)早盘涨近10%，截至发稿，涨5.13%，报6.76港元，成交额3391.17万港元。消息面上，歌礼制药公布，其自主研发的小分子口服GLP-1受体激动剂ASC30于美国进行的Ib期多剂量递增(MAD)研究取得积极顶线结果，并已向美国食品药品监督管理局(FDA)提交IIa期研究方案，预计将于2025年第三季度初开展。据悉，由歌礼自主研发的ASC30是首款也...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2529261294?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-04-24 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2529261294","market":"hk","top_or_hot":-1,"title":"港股异动 | 歌礼制药-B(01672)早盘涨近10% 治疗肥胖症药物研究获积极顶线结果 已向FDA提交IIa期研究方案","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，歌礼制药-B(01672)早盘涨近10%，截至发稿，涨5.13%，报6.76港元，成交额3391.17万港元。消息面上，歌礼制药公布，其自主研发的小分子口服GLP-1受体激动剂ASC30于美国进行的Ib期多剂量递增(MAD)研究取得积极顶线结果，并已向美国食品药品监督管理局(FDA)提交IIa期研究方案，预计将于2025年第三季度初开展。据悉，由歌礼自主研发的ASC30是首款也...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1283805.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 歌礼制药-B(01672)早盘涨近10% 治疗肥胖症药物研究获积极顶线结果 已向FDA提交IIa期研究方案</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 歌礼制药-B(01672)早盘涨近10% 治疗肥胖症药物研究获积极顶线结果 已向FDA提交IIa期研究方案\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-04-24 11:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1283805.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，歌礼制药-B(01672)早盘涨近10%，截至发稿，涨5.13%，报6.76港元，成交额3391.17万港元。消息面上，歌礼制药公布，其自主研发的小分子口服GLP-1受体激动剂ASC30于美国进行的Ib期多剂量递增(MAD)研究取得积极顶线结果，并已向美国食品药品监督管理局(FDA)提交IIa期研究方案，预计将于2025年第三季度初开展。据悉，由歌礼自主研发的ASC30是首款也...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1283805.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1283805.html","article_id":"2529261294","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2529261294","pubTimestamp":1745465512,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，歌礼制药-B早盘涨近10%，截至发稿，涨5.13%，报6.76港元，成交额3391.17万港元。消息面上，歌礼制药公布，其自主研发的小分子口服GLP-1受体激动剂ASC30于美国进行的Ib期多剂量递增研究取得积极顶线结果，并已向美国食品药品监督管理局提交IIa期研究方案，预计将于2025年第三季度初开展。ASC30是一种新化学实体，拥有美国和全球化合物专利保护，专利保护期至2044年。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","01477":"欧康维视生物-B","BK1574":"生物医药B类股","01672":"歌礼制药-B","BK1191":"制药","BK1515":"抗疫概念"},"translate_title":"Changes in Hong Kong stocks Ascletis Pharmaceuticals-B (01672) rose nearly 10% in early trading, research on obesity drugs achieved positive top-line results, and has submitted a phase IIa study plan to the FDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1,"01477":1},"content_text":"智通财经APP获悉，歌礼制药-B(01672)早盘涨近10%，截至发稿，涨5.13%，报6.76港元，成交额3391.17万港元。消息面上，歌礼制药公布，其自主研发的小分子口服GLP-1受体激动剂ASC30于美国进行的Ib期多剂量递增(MAD)研究取得积极顶线结果，并已向美国食品药品监督管理局(FDA)提交IIa期研究方案，预计将于2025年第三季度初开展。据悉，由歌礼自主研发的ASC30是首款也是唯一一款既可每日一次口服也可每月一次皮下注射的用于治疗肥胖症的在研小分子GLP-1受体(GLP-1R)激动剂。ASC30是一种新化学实体(NCE)，拥有美国和全球化合物专利保护，专利保护期至2044年。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2529261294","isCrawlerRequest":true}

港股异动 | 歌礼制药-B(01672)早盘涨近10% 治疗肥胖症药物研究获积极顶线结果 已向FDA提交IIa期研究方案

精彩评论

港股异动 | 歌礼制药-B(01672)早盘涨近10% 治疗肥胖症药物研究获积极顶线结果已向FDA提交IIa期研究方案